|
1
|
De Kouchkovsky I and Abdul-Hay M: Acute
myeloid leukemia: A comprehensive review and 2016 update. Blood
Cancer J. 6:e4412016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kadia TM, Ravandi F, Cortes J and
Kantarjian H: New drugs in acute myeloid leukemia. Ann Oncol.
27:770–778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brandt GE and Blagg BS: Alternate
strategies of Hsp90 modulation for the treatment of cancer and
other diseases. Curr Top Med Chem. 9:1447–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patki JM and Pawar SS: HSP90:
Chaperone-me-not. Pathol Oncol Res. 19:631–640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegelin MD: Inhibition of the
mitochondrial Hsp90 chaperone network: A novel, efficient treatment
strategy for cancer? Cancer Lett. 333:133–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jhaveri K and Modi S: Ganetespib: Research
and clinical development. Onco Targets Ther. 8:1849–1858.
2015.PubMed/NCBI
|
|
7
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gartner EM, Silverman P, Simon M, Flaherty
L, Abrams J, Ivy P and Lorusso PM: A phase II study of
17-allylamino-17-demethoxygeldanamycin in metastatic or locally
advanced, unresectable breast cancer. Breast Cancer Res Treat.
131:933–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walsby EJ, Lazenby M, Pepper CJ, Knapper S
and Burnett AK: The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K
and IKK signalling pathways and synergizes with cytarabine in acute
myeloid leukaemia cells. Br J Haematol. 161:57–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lancet JE, Gojo I, Burton M, Quinn M,
Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, et
al: Phase I study of the heat shock protein 90 inhibitor
alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice
weekly to patients with acute myeloid leukemia. Leukemia.
24:699–705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chandarlapaty S, Sawai A, Ye Q, Scott A,
Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, et al:
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent
antitumor activity against HER kinase-dependent cancers. Clin
Cancer Res. 14:240–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eitan Fibach, Makoto Hayashi and Sachs L:
Control of normal differentiation of myeloid leukemic cells. Proc
Natl Acad Sci USA. 70:343–346. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haanen C and Vermes I: Arsenic trioxide, a
new drug for the treatment of acute promyelocytic leukemia
resistant to tretinoine. Ned Tijdschr Geneeskd. 143:1738–1741.
1999.(In Dutch). PubMed/NCBI
|
|
14
|
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX,
Zhoa L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the
treatment of acute promyelocytic leukemia. Blood. 72:567–572.
1988.PubMed/NCBI
|
|
15
|
Wang F, Travins J, DeLaBarre B,
Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A,
Liu W, Gliser C, et al: Targeted inhibition of mutant IDH2 in
leukemia cells induces cellular differentiation. Science.
340:622–626. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okoye-Okafor UC, Bartholdy B, Cartier J,
Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A,
Wiggall KJ, et al: New IDH1 mutant inhibitors for treatment of
acute myeloid leukemia. Nat Chem Biol. 11:878–886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta K, Stefan T, Ignatz-Hoover J,
Moreton S, Parizher G, Saunthararajah Y and Wald DN: GSK-3
inhibition sensitizes acute myeloid leukemia cells to
1,25D-mediated differentiation. Cancer Res. 76:2743–2753. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sykes DB, Kfoury YS, Mercier FE, Wawer MJ,
Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, et al:
Inhibition of dihydroorotate dehydrogenase overcomes
differentiation blockade in acute myeloid leukemia. Cell.
167:171–186.e15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus
ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS,
Lekstrom-Himes JA, et al: Enhancement of hematopoietic stem cell
repopulating capacity and self-renewal in the absence of the
transcription factor C/EBP alpha. Immunity. 21:853–863. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng R, Friedman AD, Levis M, Li L, Weir
EG and Small D: Internal tandem duplication mutation of FLT3 blocks
myeloid differentiation through suppression of C/EBPalpha
expression. Blood. 103:1883–1890. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen HM, Zhang P, Voso MT, Hohaus S,
Gonzalez DA, Glass CK, Zhang DE and Tenen DG: Neutrophils and
monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood.
85:2918–2928. 1995.PubMed/NCBI
|
|
22
|
Renneville A, Roumier C, Biggio V,
Nibourel O, Boissel N, Fenaux P and Preudhomme C: Cooperating gene
mutations in acute myeloid leukemia: A review of the literature.
Leukemia. 22:915–931. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bueso-Ramos CE, Rocha FC, Shishodia S,
Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL,
Nguyen MH and Aggarwal BB: Expression of constitutively active
nuclear-κB RelA transcription factor in blasts of acute myeloid
leukemia. Hum Pathol. 35:246–253. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guzman ML, Neering SJ, Upchurch D, Grimes
B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear
factor-κB is constitutively activated in primitive human acute
myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barta TE, Veal JM, Rice JW, Partridge JM,
Fadden RP, Ma W, Jenks M, Geng L, Hanson GJ, Huang KH, et al:
Discovery of benzamide tetrahydro-4H-carbazol-4-ones as
novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett.
18:3517–3521. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Liu ZH, Xia J, Li XP, Li KQ, Xiong
W, Li J and Chen DL: 20(S)-ginsenoside Rh2 inhibits the
proliferation and induces the apoptosis of KG-1a cells through the
Wnt/β-catenin signaling pathway. Oncol Rep. 36:137–146.
2016.PubMed/NCBI
|
|
28
|
Konopleva M, Tsao T, Ruvolo P, Stiouf I,
Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, et al:
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and
differentiation in acute myelogenous leukemia. Blood. 99:326–335.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shishodia S, Sethi G, Konopleva M,
Andreeff M and Aggarwal BB: A synthetic triterpenoid, CDDO-Me,
inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF
and chemotherapeutic agents through down-regulation of expression
of nuclear factor kappaB-regulated gene products in human leukemic
cells. Clin Cancer Res. 15:1828–1838. 2006. View Article : Google Scholar
|
|
30
|
Scott LM, Civin CI, Rorth P and Friedman
AD: A novel temporal expression pattern of three C/EBP family
members in differentiating myelomonocytic cells. Blood.
80:1725–1735. 1992.PubMed/NCBI
|
|
31
|
Fisher RC and Scott EW: Role of PU.1 in
hematopoiesis. Stem Cells. 16:25–37. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerloff D, Grundler R, Wurm AA,
Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow
C, Duyster J, Tenen DG, et al: NF-κB/STAT5/miR-155 network targets
PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia.
29:535–547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jin L, Xiao CL, Lu CH, Xia M, Xing GW,
Xiong S, Liu QY, Liu H, Li YC, Ge F, et al: Transcriptomic and
proteomic approach to studying SNX-2112-induced K562 cells
apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS
Lett. 583:1859–1866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okawa Y, Hideshima T, Steed P, Vallet S,
Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, et al:
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell
growth, angiogenesis, and osteoclastogenesis in multiple myeloma
and other hematologic tumors by abrogating signaling via Akt and
ERK. Blood. 113:846–855. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roe JS and Vakoc CR: C/EBPα: Critical at
the origin of leukemic transformation. J Exp Med. 211:1–4. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rao R, Fiskus W, Yang Y, Lee P, Joshi R,
Fernandez P, Mandawat A, Atadja P, Bradner JE and Bhalla K: HDAC6
inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone
function in human leukemia cells. Blood. 112:1886–1893. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Newman B, Liu Y, Lee HF, Sun D and Wang Y:
HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.
Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iwasaki H, Somoza C, Shigematsu H, Duprez
EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, Geary K, Zhang P, Dayaram
T, et al: Distinctive and indispensable roles of PU.1 in
maintenance of hematopoietic stem cells and their differentiation.
Blood. 106:1590–1600. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou J, Zhang X, Wang Y and Guan Y: PU.1
affects proliferation of the human acute myeloid leukemia U937 cell
line by directly regulating MEIS1. Oncol Lett. 10:1912–1918.
2015.PubMed/NCBI
|
|
40
|
Cammenga J, Mulloy JC, Berguido FJ,
MacGrogan D, Viale A and Nimer SD: Induction of C/EBPalpha activity
alters gene expression and differentiation of human
CD34+ cells. Blood. 101:2206–2214. 2003. View Article : Google Scholar : PubMed/NCBI
|
